RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING H5 HEMAGGLUTININ OF AVIAN INFLUENZA VIRUS Russian patent published in 2012 - IPC C12N15/63 A61K39/12 

FIELD: medicine.

SUBSTANCE: recombinant vector of Newcastle disease virus contains an additional transcription unit including a gene coding HA protein of pathogenic avian influenza virus H5 operatively related with a gene start sequence of an initial portion of Newcastle disease virus and a gene end sequence of an end portion of Newcastle disease virus, characterised by the fact that said protein contains an elongation portion consisting of at least three essential amino acids where said elongation portion consists of arginine (Arg) and/or lysine (Lys) residues and contains at least one lysine with said gene not containing a sequence which can be recognised by a viral polymerase of Newcastle disease virus as an end gene sequence.

EFFECT: presented vector enables high expression level of HA protein of pathogenic avian influenza virus H5, as well as vaccine containing such vector provides an immune protection against Newcastle disease virus and avian influenza virus infection.

12 cl, 5 dwg, 1 tbl, 8 ex